Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;46(8):3491-3494.
doi: 10.1007/s10072-025-08194-8. Epub 2025 Apr 23.

MOG antibody-positive patients meeting diagnostic criteria for MS: is it MOGAD with an MS-like phenotype or true MS?

Hung Youl Seok  1
Affiliations
Review

MOG antibody-positive patients meeting diagnostic criteria for MS: is it MOGAD with an MS-like phenotype or true MS?

Hung Youl Seok. Neurol Sci. 2025 Aug.

Abstract

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a recently recognized disorder distinct from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder. The introduction of diagnostic criteria for MOGAD in 2023 marked a significant advance, providing high diagnostic accuracy for typical cases. However, challenges arise when patients test positive for MOG antibodies while also meeting the 2017 McDonald criteria for MS. These cases present a diagnostic dilemma, as they blur the lines between MS and MOGAD, complicating treatment decisions. This review addresses the diagnostic and management challenges faced by these patients, highlighting recent studies that underscore the difficulty in distinguishing between these two diseases and offering insights into how to approach these ambiguous cases.

Keywords: Diagnostic challenges; Multiple sclerosis; Myelin oligodendrocyte glycoprotein antibody-associated disease; Oligoclonal bands.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: None. Conflict of interest: The authors have no conflicts of interest to declare.

References

    1. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS et al (2023) Diagnosis of Myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol 22(3):268–282. https://doi.org/10.1016/S1474-4422(22)00431-8 - DOI - PubMed
    1. Filippatou AG, Said Y, Chen H, Vasileiou ES, Ahmadi G, Sotirchos ES (2024) Validation of the international MOGAD panel proposed criteria: a single-centre US study. J Neurol Neurosurg Psychiatry 95(9):870–873. https://doi.org/10.1136/jnnp-2023-333227 - DOI - PubMed
    1. Rechtman A, Freidman-Korn T, Zveik O, Shweiki L, Hoichman G, Vaknin-Dembinsky A (2024) Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings. J Neurol 271(8):5102–5108. https://doi.org/10.1007/s00415-024-12438-6 - DOI - PubMed - PMC
    1. Kim S, Eun MY, Lee JJ, Seok HY (2024) Myelin oligodendrocyte glycoprotein Antibody-Positive patients meeting the 2017 McDonald criteria for multiple sclerosis: challenges in diagnosis and treatment decisions. Ann Neurol 95(2):415. https://doi.org/10.1002/ana.26859 - DOI - PubMed
    1. Lipps P, Ayroza Galvao Ribeiro Gomes AB, Kulsvehagen L, Mutke MA, Kuhle J, Papadopoulou A, Probstel AK (2023) Ongoing challenges in the diagnosis of Myelin oligodendrocyte glycoprotein Antibody-Associated disease. JAMA Neurol 80(12):1377–1379. https://doi.org/10.1001/jamaneurol.2023.3956 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources